Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07260437 in advanced solid tumors
NCT05067972Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of PF-07260437 in breast cancer, ovarian cancer and endometrial cancer (EC) (4 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose-Limiting Toxicities at Day 42, Number of Participants With Treatment Emergent Adverse Events up to 35.1 weeks and 1 more. Started Oct 2021; status: terminated.
02
Drugs
PF-07260437
03
Conditions
breast cancerovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT05067972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067972.